BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $14 price target on ARIAD Pharmaceuticals (NASDAQ: ARIA) following a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE